Institution
University College Cork
Education•Cork, Ireland•
About: University College Cork is a education organization based out in Cork, Ireland. It is known for research contribution in the topics: Population & Irish. The organization has 12056 authors who have published 28452 publications receiving 958414 citations. The organization is also known as: Coláiste na hOllscoile Corcaigh & National University of Ireland, Cork.
Topics: Population, Irish, Gut flora, Microbiome, Casein
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The product partition model as discussed by the authors assumes that the probability of any partition is proportional to a product of prior cohesions, one for each block in the partition, and given the blocks the parameters in different blocks have independent prior distributions.
Abstract: A sequence of observations undergoes sudden changes at unknown times. We model the process by supposing that there is an underlying sequence of parameters partitioned into contiguous blocks of equal parameter values; the beginning of each block is said to be a change point. Observations are then assumed to be independent in different blocks given the sequence of parameters. In a Bayesian analysis it is necessary to give probability distributions to both the change points and the parameters. We use product partition models (Barry and Hartigan 1992), which assume that the probability of any partition is proportional to a product of prior cohesions, one for each block in the partition, and that given the blocks the parameters in different blocks have independent prior distributions. Given the observations a new product partition model holds, with posterior cohesions for the blocks and new independent block posterior distributions for parameters. The product model thus provides a convenient machinery for allo...
624 citations
••
Vrije Universiteit Brussel1, University of Copenhagen2, University of Gothenburg3, New York University4, University of Pennsylvania5, University of Helsinki6, Wageningen University and Research Centre7, Institut national de la recherche agronomique8, King's College London9, University of Maryland, Baltimore10, Waseda University11, Harvard University12, University College Cork13, University of Minnesota14, University of Texas at Austin15, University of Warwick16, Veterans Health Administration17, Stanford University18, ETH Zurich19, Shanghai Jiao Tong University20, Katholieke Universiteit Leuven21, Molecular Medicine Partnership Unit22, Max Delbrück Center for Molecular Medicine23
TL;DR: The concept of enterotypes and their use to characterize the gut microbiome are debated, a classifier and standardized methodology is provided to aid cross-study comparisons, and a balanced application of the concept is encouraged.
Abstract: Population stratification is a useful approach for a better understanding of complex biological problems in human health and wellbeing. The proposal that such stratification applies to the human gut microbiome, in the form of distinct community composition types termed enterotypes, has been met with both excitement and controversy. In view of accumulated data and re-analyses since the original work, we revisit the concept of enterotypes, discuss different methods of dividing up the landscape of possible microbiome configurations, and put these concepts into functional, ecological and medical contexts. As enterotypes are of use in describing the gut microbial community landscape and may become relevant in clinical practice, we aim to reconcile differing views and encourage a balanced application of the concept.
622 citations
••
University of Glasgow1, University of Oxford2, University of Texas Health Science Center at San Antonio3, Novartis4, Moscow State University5, University of North Carolina at Chapel Hill6, University College Cork7, Federal University of São Paulo8, National Taiwan University9, Centre Hospitalier Universitaire de Nantes10, The Chinese University of Hong Kong11, University of Leicester12, University of California, Berkeley13, University of Bern14, Tulane University15, Royal North Shore Hospital16, Medical University of Warsaw17, Harvard University18, Istanbul University19, University of Tromsø20, University of Washington21, Alfred Hospital22, University of Toronto23, University of Cape Town24, Cordoba University25, University of Illinois at Chicago26, Lahey Hospital & Medical Center27, University Medical Center Utrecht28, Umeå University29, Dresden University of Technology30, University of Liège31, Aarhus University32, Cardiovascular Institute of the South33, University of Copenhagen34, Semmelweis University35, University of Helsinki36, Duke University37
TL;DR: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.
Abstract: BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. RESULTS: The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). CONCLUSIONS: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)
620 citations
••
TL;DR: Some of the advances made, made mainly with other lactococcal bacteriocins, in improving food safety, food quality and preventing food spoilage are discussed.
620 citations
••
TL;DR: The versatility of the bacteria in the genus Stenotrophomonas is discussed and the insight that comparative genomic analysis of clinical and endophytic isolates of S. maltophilia has brought to the understanding of the adaptation of this genus to various niches is discussed.
Abstract: The genus Stenotrophomonas comprises at least eight species. These bacteria are found throughout the environment, particularly in close association with plants. Strains of the most predominant species, Stenotrophomonas maltophilia, have an extraordinary range of activities that include beneficial effects for plant growth and health, the breakdown of natural and man-made pollutants that are central to bioremediation and phytoremediation strategies and the production of biomolecules of economic value, as well as detrimental effects, such as multidrug resistance, in human pathogenic strains. Here, we discuss the versatility of the bacteria in the genus Stenotrophomonas and the insight that comparative genomic analysis of clinical and endophytic isolates of S. maltophilia has brought to our understanding of the adaptation of this genus to various niches.
619 citations
Authors
Showing all 12300 results
Name | H-index | Papers | Citations |
---|---|---|---|
Stephen J. O'Brien | 153 | 1062 | 93025 |
James J. Collins | 151 | 669 | 89476 |
J. Wouter Jukema | 124 | 785 | 61555 |
John F. Cryan | 124 | 723 | 58938 |
Fergus Shanahan | 117 | 705 | 51963 |
Timothy G. Dinan | 116 | 689 | 60561 |
John M. Starr | 116 | 695 | 48761 |
Gordon G. Wallace | 114 | 1267 | 69095 |
Colin Hill | 112 | 693 | 54484 |
Robert Clarke | 111 | 512 | 90049 |
Douglas B. Kell | 111 | 634 | 50335 |
Thomas Bein | 109 | 677 | 42800 |
Steven C. Hayes | 106 | 450 | 51556 |
Åke Borg | 105 | 444 | 53835 |
Eamonn Martin Quigley | 103 | 685 | 39585 |